Browse
Submit Data
Databases
API
Help

Dataset Information

22 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Anti-amyloid-?-mediated positron emission tomography imaging in Alzheimer's disease mouse brains.

ABSTRACT: Antibody-mediated imaging of amyloid ? (A?) in Alzheimer's disease (AD) offers a promising strategy to detect and monitor specific A? species, such as oligomers, that have important pathological and therapeutic relevance. The major current limitation of antibodies as a diagnostic and imaging device is poor blood-brain-barrier permeability. A classical anti-A? antibody, 6E10, is modified with 10 kDa polyethylene glycol (PEG) and a positron emitting isotope, Copper-64 (t(½)?=?12.7 h), and intravenously delivered to the TgCRND8 mouse model of Alzheimer's disease. Modification of 6E10 with PEG (6E10-PEG) increases accumulation of 6E10 in brain tissue in both TgCRND8 and wild type control animals. 6E10-PEG differentiates TgCRND8 animals from wild type controls using positron emission tomography (PET) and provides a framework for using antibodies to detect pathology using non-invasive medical imaging techniques.

SUBMITTER: McLean D

PROVIDER: S-EPMC3528731 | biostudies-literature | 2012

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Publications

Anti-amyloid-β-mediated positron emission tomography imaging in Alzheimer's disease mouse brains.

McLean Daniel D Cooke Michael J MJ Wang Yuanfei Y Green David D Fraser Paul E PE George-Hyslop Peter St PS Shoichet Molly S MS

PloS one 20121221 12

Antibody-mediated imaging of amyloid β (Aβ) in Alzheimer's disease (AD) offers a promising strategy to detect and monitor specific Aβ species, such as oligomers, that have important pathological and therapeutic relevance. The major current limitation of antibodies as a diagnostic and imaging device is poor blood-brain-barrier permeability. A classical anti-Aβ antibody, 6E10, is modified with 10 kDa polyethylene glycol (PEG) and a positron emitting isotope, Copper-64 (t(½) = 12.7 h), and intraven ...[more]

PMID: 23284831

Similar Datasets

Amyloid and metabolic positron emission tomography imaging of cognitively normal adults with Alzheimer's parents.

Project description:This study examines the relationship between fibrillar beta-amyloid (A?) deposition and reduced glucose metabolism, a proxy for neuronal dysfunction, in cognitively normal (NL) individuals with a parent affected by late-onset Alzheimer's disease (AD). Forty-seven 40-80-year-old NL received positron emission tomography (PET) with (11)C-Pittsburgh compound B (PiB) and 18F-fluoro-2-deoxy-d-glucose (FDG). These included 19 NL with a maternal history (MH), 12 NL with a paternal history (PH), and 16 NL with negative family history of AD (NH). Automated regions of interest, statistical parametric mapping, voxel-wise intermodality correlations, and logistic regressions were used to examine cerebral-to-cerebellar PiB and FDG standardized uptake value ratios across groups. The MH group showed higher PiB retention and lower metabolism in AD regions compared with NH and PH, which were negatively correlated in posterior cingulate, frontal, and parieto-temporal regions (Pearson r ? -0.57, p ? 0.05). No correlations were observed in NH and PH. The combination of A? deposition and metabolism yielded accuracy ? 69% for MH vs. NH and ? 71% for MH vs. PH, with relative risk = 1.9-5.1 (p values < 0.005). NL individuals with AD-affected mothers show co-occurring A? increases and hypometabolism in AD-vulnerable regions, suggesting an increased risk for AD.

| S-EPMC3402654 | biostudies-literature

Plasma amyloid assay as a pre-screening tool for amyloid positron emission tomography imaging in early stage Alzheimer's disease.

Project description:INTRODUCTION:Due to the high cost and high failure rate of ascertaining amyloid positron emission tomography positivity (PET+) in patients with earlier stage Alzheimer's disease (AD), an effective pre-screening tool for amyloid PET scans is needed. METHODS:Patients with mild cognitive impairment (n?=?33, 24.2% PET+, 42% females, age 74.4?±?7.5, MMSE 26.8?±?1.9) and mild dementia (n?=?19, 63.6% PET+, 36.3% females, age 73.0?±?9.3, MMSE 22.6?±?2.0) were recruited. Amyloid PET imaging, Apolipoprotein E (APOE) genotyping, and plasma amyloid ? (A?)1-40, A?1-42, and total tau protein quantification by immunomagnetic reduction (IMR) method were performed. Receiver operating characteristics (ROC) analysis and Youden's index were performed to identify possible cut-off points, clinical sensitivities/specificities, and areas under the curve (AUCs). RESULTS:Amyloid PET+ participants had lower plasma A?1-42 levels than amyloid PET-negative (PET-) subjects. APOE ?4 carriers had higher plasma A?1-42 than non-carriers. We developed an algorithm involving the combination of plasma A?1-42 and APOE genotyping. The success rate for detecting amyloid PET+ patients effectively increased from 42.3 to 70.4% among clinically suspected MCI and mild dementia patients. CONCLUSIONS:Our results demonstrate the possibility of utilizing APOE genotypes in combination with plasma A?1-42 levels as a pre-screening tool for predicting the positivity of amyloid PET findings in early stage dementia patients.

| S-EPMC6933740 | biostudies-literature

Comparing positron emission tomography imaging and cerebrospinal fluid measurements of ?-amyloid.

Project description:We examined agreement and disagreement between 2 biomarkers of ?-amyloid (A?) deposition (amyloid positron emission tomography [PET] and cerebrospinal fluid [CSF] A?1-42 ) in normal aging and dementia in a large multicenter study.Concurrently acquired florbetapir PET and CSF A? were measured in cognitively normal, mild cognitive impairment (MCI), and Alzheimer's disease participants (n?=?374) from the Alzheimer's Disease Neuroimaging Initiative. We also compared A? measurements in a separate group with serial CSF measurements over 3.1?±?0.8 years that preceded a single florbetapir session. Additional biomarker and cognitive data allowed us to further examine profiles of discordant cases.Florbetapir and CSF A? were inversely correlated across all diagnostic groups, and dichotomous measurements were in agreement in 86% of subjects. Among subjects showing the most disagreement, the 2 discordant groups had different profiles: the florbetapir(+) /CSF A?(-) group was larger (n?=?13) and was made up of only normal and early MCI subjects, whereas the florbetapir(-) /CSF A?(+) group was smaller (n?=?7) and had poorer cognitive function and higher CSF tau, but no ApoE4 carriers. In the longitudinal sample, we observed both stable longitudinal CSF A? trajectories and those actively transitioning from normal to abnormal, but the final CSF A? measurements were in good agreement with florbetapir cortical retention.CSF and amyloid PET measurements of A? were consistent in the majority of subjects in the cross-sectional and longitudinal populations. Based on our analysis of discordant subjects, the available evidence did not show that CSF A? regularly becomes abnormal prior to fibrillar A? accumulation early in the course of disease.

| S-EPMC3748164 | biostudies-literature

Different aspects of Alzheimer's disease-related amyloid ?-peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia.

Project description:Alzheimer's disease (AD)-related amyloid ?-peptide (A?) pathology in the form of amyloid plaques and cerebral amyloid angiopathy (CAA) spreads in its topographical distribution, increases in quantity, and undergoes qualitative changes in its composition of modified A? species throughout the pathogenesis of AD. It is not clear which of these aspects of A? pathology contribute to AD progression and to what extent amyloid positron emission tomography (PET) reflects each of these aspects. To address these questions three cohorts of human autopsy cases (in total n?=?271) were neuropathologically and biochemically examined for the topographical distribution of A? pathology (plaques and CAA), its quantity and its composition. These parameters were compared with neurofibrillary tangle (NFT) and neuritic plaque pathology, the degree of dementia and the results from [18F]flutemetamol amyloid PET imaging in cohort 3. All three aspects of A? pathology correlated with one another, the estimation of A? pathology by [18F]flutemetamol PET, AD-related NFT pathology, neuritic plaques, and with the degree of dementia. These results show that one aspect of A? pathology can be used to predict the other two, and correlates well with the development of dementia, advancing NFT and neuritic plaque pathology. Moreover, amyloid PET estimates all three aspects of A? pathology in-vivo. Accordingly, amyloid PET-based estimates for staging of amyloid pathology indicate the progression status of amyloid pathology in general and, in doing so, also of AD pathology. Only 7.75% of our cases deviated from this general association.

| S-EPMC6854805 | biostudies-literature

Tau Positron Emission Tomography Imaging.

Project description:Alzheimer's disease (AD) is a chronic neurodegenerative disorder and the most common cause of dementia among the elderly population. The good correlation between the density and neocortical spread of neurofibrillary tangles (NFTs) and the severity of cognitive impairment offers an opportunity to use a noninvasive imaging technique such as positron emission tomography (PET) for early diagnosis and staging of the disease. PET imaging of NFTs holds promise not only as a diagnostic tool but also because it may enable the development of disease-modifying therapeutics for AD. In this review, we focus on the structural diversity of tau PET tracers, the challenges related to identifying high-affinity and highly selective NFT ligands, and recent progress in the clinical development of tau PET radioligands.

| S-EPMC5411699 | biostudies-literature

Tracking neuroinflammation in Alzheimer's disease: the role of positron emission tomography imaging.

Project description:Alzheimer's disease (AD) has been reconceptualized as a dynamic pathophysiological process, where the accumulation of amyloid-beta (A?) is thought to trigger a cascade of neurodegenerative events resulting in cognitive impairment and, eventually, dementia. In addition to A? pathology, various lines of research have implicated neuroinflammation as an important participant in AD pathophysiology. Currently, neuroinflammation can be measured in vivo using positron emission tomography (PET) with ligands targeting diverse biological processes such as microglial activation, reactive astrocytes and phospholipase A2 activity. In terms of therapeutic strategies, despite a strong rationale and epidemiological studies suggesting that the use of non-steroidal anti-inflammatory drugs (NSAIDs) may reduce the prevalence of AD, clinical trials conducted to date have proven inconclusive. In this respect, it has been hypothesized that NSAIDs may only prove protective if administered early on in the disease course, prior to the accumulation of significant AD pathology. In order to test various hypotheses pertaining to the exact role of neuroinflammation in AD, studies in asymptomatic carriers of mutations deterministic for early-onset familial AD may prove of use. In this respect, PET ligands for neuroinflammation may act as surrogate markers of disease progression, allowing for the development of more integrative models of AD, as well as for the measuring of target engagement in the context of clinical trials using NSAIDs. In this review, we address the biological basis of neuroinflammatory changes in AD, underscore therapeutic strategies using anti-inflammatory compounds, and shed light on the possibility of tracking neuroinflammation in vivo using PET imaging ligands.

| S-EPMC4099095 | biostudies-literature

Imaging Inflammation with Positron Emission Tomography.

Project description:The impact of inflammation on the outcome of many medical conditions such as cardiovascular diseases, neurological disorders, infections, cancer, and autoimmune diseases has been widely acknowledged. However, in contrast to neurological, oncologic, and cardiovascular disorders, imaging plays a minor role in research and management of inflammation. Imaging can provide insights into individual and temporospatial biology and grade of inflammation which can be of diagnostic, therapeutic, and prognostic value. There is therefore an urgent need to evaluate and understand current approaches and potential applications for imaging of inflammation. This review discusses radiotracers for positron emission tomography (PET) that have been used to image inflammation in cardiovascular diseases and other inflammatory conditions with a special emphasis on radiotracers that have already been successfully applied in clinical settings.

| S-EPMC7922638 | biostudies-literature

Positron emission tomography imaging of fibrillar parenchymal and vascular amyloid-? in TgCRND8 mice.

Project description:Few quantitative diagnostic and monitoring, tools are available to clinicians treating patients with Alzheimer's disease. Further, many of the promising quantitative imaging tools under development lack clear specificity toward different types of Amyloid-? (A?) pathology such as vascular or oligomeric species. Antibodies offer an opportunity to image specific types of A? pathology because of their excellent specificity. In this study, we developed a method to translate a panel of anti-A? antibodies, which show excellent histological performance, into live animal imaging contrast agents. In the TgCRND8 mouse model of Alzheimer's disease, we tested two antibodies, M64 and M116, that target parenchyma aggregated A? plaques and one antibody, M31, that targets vascular A?. All three antibodies were administered intravenously after labeling with both poly(ethylene glycol) to enhance circulation and (64)Cu to allow detection via positron emission tomography (PET) imaging. We were clearly able to differentiate TgCRND8 mice from wild type controls by PET imaging using either M116, the anti-A? antibody targeting parenchymal A? or M31, the antivascular A? antibody. To confirm the validity of the noninvasive imaging of specific A? pathology, brains were examined after imaging and showed clear evidence of binding to A? plaques.

| S-EPMC3629748 | biostudies-literature

Detection of amyloid in Alzheimer's disease with positron emission tomography using [11C]AZD2184.

Project description:PURPOSE: Current positron emission tomography (PET) radioligands for detection of Abeta amyloid in Alzheimer's disease (AD) are not ideal for quantification. To improve the signal to noise ratio we have developed the radioligand [(11)C]AZD2184 and report here the first clinical evaluation. METHODS: Eight AD patients and four younger control subjects underwent 93-min PET measurements with [(11)C]AZD2184. A ratio approach using the cerebellum as reference region was applied to determine binding parameters. RESULTS: Brain uptake of [(11)C]AZD2184 peaked within 1 min at 3-4% of injected radioactivity. AD patients had high radioactivity in cortical regions while controls had uniformly low radioactivity uptake. Specific binding peaked within 30 min at which time standardized uptake value ratios (SUVR) ranged between 1.19 and 2.57. CONCLUSION: [(11)C]AZD2184 is a promising radioligand for detailed mapping of Abeta amyloid depositions in Alzheimer's disease, due to low non-specific binding, high signal to background ratio and reversible binding as evident from early peak equilibrium.

| S-EPMC2764092 | biostudies-other

Positron emission tomography imaging of coronary atherosclerosis.

Project description:Inflammation has a central role in the progression of coronary atherosclerosis. Recent developments in cardiovascular imaging with the advent of hybrid positron emission tomography have provided a window into the molecular pathophysiology underlying coronary plaque inflammation. Using novel radiotracers targeted at specific cellular pathways, the potential exists to observe inflammation, apoptosis, cellular hypoxia, microcalcification and angiogenesis in vivo. Several clinical studies are now underway assessing the ability of this hybrid imaging modality to inform about atherosclerotic disease activity and the prediction of future cardiovascular risk. A better understanding of the molecular mechanisms governing coronary atherosclerosis may be the first step toward offering patients a more stratified, personalized approach to treatment.

| S-EPMC4926532 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data